THE QT INTERVAL AND DRUG-ASSOCIATED TORSADES-DE-POINTES

被引:41
作者
BENEDICT, CR
机构
[1] Division of Cardiology, The University of Texas Medical School, Houston, Texas
来源
DRUG INVESTIGATION | 1993年 / 5卷 / 01期
关键词
D O I
10.1007/BF03259230
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Torsades de pointes is an uncommon form of ventricular tachyarrhythmia, which may occur in the presence or absence of drug therapy. There are several difficulties in establishing a relationship between drug therapy and the induction of this arrhythmia. Drugs for which a definitive association with torsades de pointes are established, i.e. class IA and III antiarrhythmics, are known to prolong the QT or QT(c) interval. However, the definition of significant QT or QT(c) prolongation is sometimes difficult because there is a significant inter- and intrapatient variability in the observed QT or QT(c) interval even in the absence of drug therapy. Furthermore, some drugs that induce prolongation of the QT or QT(c) interval in a given patient do not precipitate torsades de pointes. Recent reports of unexpected drug-induced torsades de pointes by drugs other than class IA or III antiarrhythmics led to the examination of the association between QT interval prolongation and torsades de pointes, and evaluation of the mechanisms for drug-induced torsades de pointes by drugs other than class IA or III antiarrhythmic drugs.
引用
收藏
页码:69 / 79
页数:11
相关论文
共 82 条
  • [71] Smith W.M., Gallagher J.J., ‘Les Torsades de Pointes’: an unusual ventricular arrhythmia, Annals of Internal Medicine, 93, pp. 578-584, (1980)
  • [72] Staniforth D.H., The QT interval and cycle length: The influence of atropine, hyoscine and exercise, British Journal of Clinical Pharmacology, 16, pp. 615-621, (1983)
  • [73] Stein K.M., Haronian H., Mensah G.A., Et al., Ventricular tachycardia and torsades de pointes complicating pentamidine therapy of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome, American Journal of Cardiology, 66, pp. 888-889, (1990)
  • [74] Stern S., Keren A., Tzivoni D., Torsades de pointes: definitions, causative factors, and therapy: experience with sixteen patients, Annals of the New York Academy of Sciences, 427, pp. 234-240, (1984)
  • [75] Strasberg B., Coelho A., Welch W., Et al., Doxepin-induced torsades de pointes, PACE, 5, (1982)
  • [76] Strasberg B., Sclarovsky S., Erdberg A., Et al., Procainamide-induced polymorphous ventricular tachycardia, American Journal of Cardiology, 47, pp. 1309-1314, (1981)
  • [77] Stratmann H.G., Kennedy H.L., Torsades de pointes associated with drugs and toxins: recognition and management, American Heart Journal, 113, pp. 1470-1481, (1987)
  • [78] Surawicz B., Knoebel S.B., Long QT: good, bad, or indifferent?, Journal of the American College of Cardiology, 4, pp. 398-413, (1984)
  • [79] Wellens H.J.J., Vermeulen A., Durrer D., Ventricular fibrillation occurring on arousal from sleep by auditory stimuli, Circulation, 46, pp. 661-665, (1972)
  • [80] Zilcher H., Glogar D., Kaindl F., Torsades de pointes: occurrence in myocardial ischaemia as a separate entity. Multiform ventricular tachycardia or not?, European Heart Journal, 1, pp. 1280-1283, (1984)